TRANSFORM’s research has direct implications for policy and practice. MedSafe has recently recommended cytisine as a pharmacy-only medication for nicotine dependence in New Zealand.
This decision is a direct result of years of research on cytisine for smoking cessation led by TRANSFORM member Professor Natalie Walker, with support from Professors Chris Bullen, Jo Barnes, Malcom Tingle, Janie Sheridan, plus Associate Professor George Laking, Varsha Parag, and many others.
Cytisine is widely available in Europe, and more recently in Australia and Canada. It is also known as cytisinicline, baptitoxine, and sophorine. Medsafe’s decision is one step forward on the track towards cytisine becoming available in New Zealand.
Read more about Cytisine versus Nicotine for Smoking Cessation